Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 24;25(6):168.
doi: 10.1208/s12249-024-02883-x.

Current Trends and Innovative Approaches in Cancer Immunotherapy

Jaechang Kim  1 , Ruby Maharjan  1 , Jonghyuck Park  2   3   4
Affiliations
Review

Current Trends and Innovative Approaches in Cancer Immunotherapy

Jaechang Kim et al. AAPS PharmSciTech. .

Abstract

Immunotherapy is one of the most promising therapeutic approaches in the field of cancer treatment. As a tumor progresses, tumor cells employ an array of immune-regulatory mechanisms to suppress immune responses within the tumor microenvironment. Using our understanding of these mechanisms, cancer immunotherapy has been developed to enhance the immune system's effectiveness in treating cancer. Numerous cancer immunotherapies are currently in clinical use, yet many others are either in different stages of development or undergoing clinical studies. In this paper, we briefly discuss the features and current status of cancer immunotherapies. This includes the application of monoclonal antibodies, immune checkpoint inhibitors, adoptive cell therapy, cytokine therapy, cancer vaccines, and gene therapy, all of which have gained significant recognition in clinical practice. Additionally, we discuss limitations that may hinder successful clinical utilization and promising strategies, such as combining immunotherapy with nanotechnology.

Keywords: cancer immunotherapy; combination therapy; immunomodulation.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. https://doi.org/10.3389/fimmu.2023.1212476 . - DOI - PubMed - PMC
    1. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9. https://doi.org/10.1177/20503121211034366 .
    1. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm. 2011;26(1):1–64. https://doi.org/10.1089/cbr.2010.0902 . - DOI - PubMed
    1. Sambi M, Bagheri L, Szewczuk MR. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J Oncol. 2019;2019:4508794. https://doi.org/10.1155/2019/4508794 . - DOI - PubMed - PMC
    1. Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018;9(10):1773–81. https://doi.org/10.7150/jca.24577 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources